{"id":36749,"date":"2025-07-04T18:13:33","date_gmt":"2025-07-04T10:13:33","guid":{"rendered":"https:\/\/flcube.com\/?p=36749"},"modified":"2025-07-04T18:13:33","modified_gmt":"2025-07-04T10:13:33","slug":"eli-lillys-mounjaro-approved-by-chinas-nmpa-for-obstructive-sleep-apnea-in-obese-adults","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=36749","title":{"rendered":"Eli Lilly’s Mounjaro Approved by China’s NMPA for Obstructive Sleep Apnea in Obese Adults"},"content":{"rendered":"\n

US pharma giant Eli Lilly & Co. (NYSE: LLY<\/a>) announced that it has received a new market approval from China’s National Medical Products Administration (NMPA) for its drug Mounjaro (tirzepatide). The approval is for the treatment of moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, to be used in conjunction with dietary control and increased physical activity. Tirzepatide has demonstrated effectiveness in improving sleep disturbances in this patient population.<\/p>\n\n\n\n

Clinical Trial Results<\/strong>
The approval was supported by results from the global, multi-center Phase III SURMOUNT-OSA study. In the study, tirzepatide significantly reduced apnea-hypopnea events per hour (AHI) by 27 events\/hour in patients not using positive airway pressure (PAP) therapy (vs. 5 events\/hour in placebo) and by 30 events\/hour in patients using PAP therapy (vs. 6 events\/hour in placebo). After one year of treatment, 43% of non-PAP users and 52% of PAP users achieved symptom resolution, far exceeding the placebo group (15% and 14%, respectively). Additionally, patients experienced average weight loss of 18.1%-20.1%.<\/p>\n\n\n\n

Significance of Approval<\/strong>
This marks the third approved indication for tirzepatide in China, making it the first and only prescription drug approved for OSA in this patient population. This addresses a critical unmet medical need. Previously, tirzepatide was approved in China for type 2 diabetes and chronic weight management.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

US pharma giant Eli Lilly & Co. (NYSE: LLY) announced that it has received a…<\/p>\n","protected":false},"author":1,"featured_media":36750,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[199,911,86,15],"class_list":["post-36749","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-eli-lilly","tag-nyse-lly","tag-obesity","tag-product-approvals"],"yoast_head":"\nEli Lilly's Mounjaro Approved by China's NMPA for Obstructive Sleep Apnea in Obese Adults - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US pharma giant Eli Lilly & Co. (NYSE: LLY) announced that it has received a new market approval from China's National Medical Products Administration (NMPA) for its drug Mounjaro (tirzepatide). The approval is for the treatment of moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, to be used in conjunction with dietary control and increased physical activity. Tirzepatide has demonstrated effectiveness in improving sleep disturbances in this patient population.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=36749\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eli Lilly's Mounjaro Approved by China's NMPA for Obstructive Sleep Apnea in Obese Adults\" \/>\n<meta property=\"og:description\" content=\"US pharma giant Eli Lilly & Co. (NYSE: LLY) announced that it has received a new market approval from China's National Medical Products Administration (NMPA) for its drug Mounjaro (tirzepatide). The approval is for the treatment of moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, to be used in conjunction with dietary control and increased physical activity. Tirzepatide has demonstrated effectiveness in improving sleep disturbances in this patient population.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=36749\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-04T10:13:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0419.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36749#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36749\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Eli Lilly’s Mounjaro Approved by China’s NMPA for Obstructive Sleep Apnea in Obese Adults\",\"datePublished\":\"2025-07-04T10:13:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36749\"},\"wordCount\":228,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36749#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0419.webp\",\"keywords\":[\"Eli Lilly\",\"NYSE: LLY\",\"Obesity\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=36749#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36749\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=36749\",\"name\":\"Eli Lilly's Mounjaro Approved by China's NMPA for Obstructive Sleep Apnea in Obese Adults - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36749#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36749#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0419.webp\",\"datePublished\":\"2025-07-04T10:13:33+00:00\",\"description\":\"US pharma giant Eli Lilly & Co. (NYSE: LLY) announced that it has received a new market approval from China's National Medical Products Administration (NMPA) for its drug Mounjaro (tirzepatide). The approval is for the treatment of moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, to be used in conjunction with dietary control and increased physical activity. Tirzepatide has demonstrated effectiveness in improving sleep disturbances in this patient population.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36749#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=36749\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36749#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0419.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0419.webp\",\"width\":1080,\"height\":608,\"caption\":\"Eli Lilly's Mounjaro Approved by China's NMPA for Obstructive Sleep Apnea in Obese Adults\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36749#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eli Lilly’s Mounjaro Approved by China’s NMPA for Obstructive Sleep Apnea in Obese Adults\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Eli Lilly's Mounjaro Approved by China's NMPA for Obstructive Sleep Apnea in Obese Adults - Insight, China's Pharmaceutical Industry","description":"US pharma giant Eli Lilly & Co. (NYSE: LLY) announced that it has received a new market approval from China's National Medical Products Administration (NMPA) for its drug Mounjaro (tirzepatide). The approval is for the treatment of moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, to be used in conjunction with dietary control and increased physical activity. Tirzepatide has demonstrated effectiveness in improving sleep disturbances in this patient population.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=36749","og_locale":"en_US","og_type":"article","og_title":"Eli Lilly's Mounjaro Approved by China's NMPA for Obstructive Sleep Apnea in Obese Adults","og_description":"US pharma giant Eli Lilly & Co. (NYSE: LLY) announced that it has received a new market approval from China's National Medical Products Administration (NMPA) for its drug Mounjaro (tirzepatide). The approval is for the treatment of moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, to be used in conjunction with dietary control and increased physical activity. Tirzepatide has demonstrated effectiveness in improving sleep disturbances in this patient population.","og_url":"https:\/\/flcube.com\/?p=36749","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-07-04T10:13:33+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0419.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=36749#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=36749"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Eli Lilly’s Mounjaro Approved by China’s NMPA for Obstructive Sleep Apnea in Obese Adults","datePublished":"2025-07-04T10:13:33+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=36749"},"wordCount":228,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=36749#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0419.webp","keywords":["Eli Lilly","NYSE: LLY","Obesity","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=36749#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=36749","url":"https:\/\/flcube.com\/?p=36749","name":"Eli Lilly's Mounjaro Approved by China's NMPA for Obstructive Sleep Apnea in Obese Adults - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=36749#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=36749#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0419.webp","datePublished":"2025-07-04T10:13:33+00:00","description":"US pharma giant Eli Lilly & Co. (NYSE: LLY) announced that it has received a new market approval from China's National Medical Products Administration (NMPA) for its drug Mounjaro (tirzepatide). The approval is for the treatment of moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, to be used in conjunction with dietary control and increased physical activity. Tirzepatide has demonstrated effectiveness in improving sleep disturbances in this patient population.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=36749#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=36749"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=36749#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0419.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0419.webp","width":1080,"height":608,"caption":"Eli Lilly's Mounjaro Approved by China's NMPA for Obstructive Sleep Apnea in Obese Adults"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=36749#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Eli Lilly’s Mounjaro Approved by China’s NMPA for Obstructive Sleep Apnea in Obese Adults"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0419.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/36749","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=36749"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/36749\/revisions"}],"predecessor-version":[{"id":36751,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/36749\/revisions\/36751"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/36750"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=36749"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=36749"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=36749"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}